exudates and Triple-Negative-Breast-Neoplasms

exudates has been researched along with Triple-Negative-Breast-Neoplasms* in 3 studies

Other Studies

3 other study(ies) available for exudates and Triple-Negative-Breast-Neoplasms

ArticleYear
Genetic Association of CYP1B1 4326 C>G Polymorphism with Disease-Free Survival in TNBC Patients Undergoing TAC Chemotherapy Regimen.
    Asian Pacific journal of cancer prevention : APJCP, 2021, Apr-01, Volume: 22, Issue:4

    Triple negative breast cancer (TNBC) which is treated with taxane, adriamycin and cyclophosphamide (TAC) chemotherapy regimen show variation in treatment response. CYP1B1 4326 C>G polymorphism has been implicated in contributing to the differences in treatment response in various types of cancers.. The objective of the present study was to investigate whether this polymorphism modulate the risk of disease recurrence in TNBC patients undergoing TAC chemotherapy regimen.. Blood samples of 76 immunohistochemistry confirmed TNBC patients were recruited. The genotyping of CYP1B1 4326 C>G polymorphism was carried out using PCR-RFLP technique. The genotype patterns were categorized into homozygous wildtype, heterozygous and homozygous variant. Kaplan-Meier analysis followed by Cox proportional hazard regression model were performed to evaluate the TNBC patients' recurrence risk.. Out of 76 TNBC patients, 25 (33.0%) showed disease recurrence after one-year evaluation. Kaplan Meier analysis showed that TNBC patients who are carriers of CYP1B1 4326 GG variant genotypes (37.0%) had a significantly lower probability of disease-free rates as compared to TNBC patients who are carriers of CYP1B1 4326 CC/CG genotypes (71.0%). Univariate and multivariate Cox analysis demonstrated that TNBC patients who carried CYP1B1 4326 GG variant genotype had a significantly higher risk of recurrence with HR: 2.50 and HR: 4.18 respectively, even after adjustment as compared to TNBC patients who were carriers of CYP1B1 4326 CC and CG genotypes.. Our results demonstrate the potential use of CYP1B1 4325 GG variant genotype as a candidate biomarker in predicting risk of recurrence in TNBC patients undergoing TAC chemotherapy regimen.

    Topics: Adult; Antineoplastic Agents; Bridged-Ring Compounds; Cyclophosphamide; Cytochrome P-450 CYP1B1; Disease-Free Survival; Doxorubicin; Female; Genotype; Humans; Malaysia; Middle Aged; Neoplasm Recurrence, Local; Polymorphism, Single Nucleotide; Taxoids; Triple Negative Breast Neoplasms

2021
Incidence and prognosis of non-metastatic triple negative breast cancer (TNBC) among different races in Southeast Asia.
    Journal of surgical oncology, 2017, Volume: 115, Issue:5

    Triple negative breast cancer (TNBC) carries a worse prognosis compared to the other subtypes. There have been conflicting studies that race may impact the prognosis of TNBC patients. We aim to determine the incidence and prognosis of TNBC among the different ethnic races in Singapore, and to determine its associated risk factors for prognosis.. Patients diagnosed with invasive breast cancer (BC) from 2005 to 2013 at our tertiary institution were included and divided according to race and subtypes. Demographic and clinical information of non-metastatic TNBC patients were analyzed. Log-rank test, univariate and multivariate Cox proportional hazard regression models were used to find associated risk factors related with overall survival (OS) and disease-free survival (DFS).. Among 1227 BC patients, 129 (10.5%) had TNBC. TNBC patients had the worst OS (P: 0.0005) and DFS (P: 0.0016) among the subtypes. However, variations in race did not have any difference in OS or DFS among TNBC patients. Axillary lymph node involvement, invasive lobular histology, larger tumor size, and the presence of lymphovascular invasion (LVI) were factors associated with both poor DFS and OS among TNBC patients.. Racial variation did not have any impact on the prognosis of the TNBC.

    Topics: Adenocarcinoma, Mucinous; Adult; Aged; Aged, 80 and over; Asian People; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Chemotherapy, Adjuvant; China; Female; Follow-Up Studies; Humans; Incidence; India; Lymph Node Excision; Lymph Nodes; Malaysia; Mastectomy; Mastectomy, Segmental; Middle Aged; Neoplasm Invasiveness; Prognosis; Proportional Hazards Models; Radiotherapy, Adjuvant; Risk Factors; Singapore; Triple Negative Breast Neoplasms; White People

2017
Triple negative breast cancer: the role of metabolic pathways.
    The Malaysian journal of pathology, 2014, Volume: 36, Issue:3

    The incidence of breast cancer in Malaysia and other Asian countries is on the increase, reflecting lifestyle changes some of which are known risk factors for the development of breast cancer. Most breast cancers are amenable to adjuvant therapies that target hormone receptors or HER2 receptors on the surface of the cancer cells and bring about significant improvement in survival. However, approximately 17% of Malaysian women with breast cancer, present with tumours that are devoid of these receptors and are consequently termed 'triple negative' breast cancers. These triple negative breast cancers typically occur in women of a younger age than receptor positive cancers, are predominantly of high grade tumours and the prognosis is usually poor. There is therefore a pressing need to understand the biological pathways that drive these tumours, in order that effective strategies are developed to treat these aggressive tumours. With the increasing affluence of developing countries, obesity and Type II Diabetes are also on the rise. These diseases are associated with an increased risk of developing a range of cancers including those of the breast. In particular, the metabolic syndrome has been shown to be associated with triple negative breast cancer. This article reviews some of the metabolic pathways and biomarkers which have been shown to be aberrantly expressed in triple negative breast cancer and highlights some of the ongoing work in this area.

    Topics: Diabetes Mellitus, Type 2; Female; Humans; Malaysia; Obesity; Prognathism; Risk Factors; Triple Negative Breast Neoplasms

2014